ArticleMaterials today. Bio2025
A hybrid implant combining a macroporous device with immunoprotective microcapsules for cell therapy applications: A conceptual in vitro study.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell encapsulation strategies including macro- and micro-delivery devices have been widely used in cell therapy due to their ability to provide immunoprotection to the transplanted cells. While both strategies can provide mechanical and physiochemical support for maintaining cell survival and function, they each have their limitations. In this study, we report the design and fabrication of a hybrid implant combining the advantages of both macro- and micro-cell delivery devices. The hybrid implant comprises a microwell-array macroporous device fabricated from non-degradable clinically approved polyvinylidene fluoride (PVDF) combined with immunoprotective alginate microcapsules. The microwell design provides a vessel to retain individual microcapsules, while the pores enable unhindered mass transport of nutrients and oxygen to the encapsulated cells and support vascular ingrowth. We show that both rodent pseudoislets and primary human islets maintain their viability and function inside the hybrid implant in a proof-of-concept study. Mechanically, it is strong and flexible suitable for surgical handling and for eventual retrieval for replacement. The hybrid implant also supports the growth of human umbilical vein endothelial cells (HUVEC) across its surface allowing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.